



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of : Himmelsbach, F. et al) Art Unit: 1624
Serial No. : 09/934,631) Examiner:
Confirmation No. : 8655
Filed : 08/22/2001
For : Aminoquinazolines Which Inhibit Signal Transduction Mediated By Tyrosine Kinases
Docket No. : 5/1303

1624
#5
3/16/2
RECEIVED
MAR 14 2002
TECH CENTER 1600/2900

Commissioner for Patents
Washington, D.C. 20231

October 19, 2001

TRANSMITTAL LETTER FOR INFORMATION DISCLOSURE STATEMENT

Sir:


Transmitted herewith concerning the subject application is an Information Disclosure Statement under 37 C.F.R. §§1.56 and

☒ 1.97(b). This Statement is being filed within three months of the filing date of a national application; within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in an international application; or before the mailing of a first Office Action on the merits, whichever event occurs last.

☒ The Assistant Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. §1.16 and any patent application processing fees under 37 C.F.R. §1.17, or credit any overpayment of same, to Deposit Account No. 02-2955.

Triplicate copies of this form are enclosed.

Respectfully submitted,



Alan R. Stempel
Attorney for Applicant(s)
Reg. No. 28,991

Patent Department
Boehringer Ingelheim Corp.
900 Ridgebury Road, P.O. Box 368
Ridgefield, CT. 06877
Tel.: (203) 798-4868

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents
Washington, DC 20231

on October 19, 2001


By: Alan R. Stempel, Reg. No. 28,991